Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ABSI

Absci

ABSI Lead: Phase 1 4 Biotech Distilled articles ↓ 23 filings & releases ↓ Cash $108M (Jun 30, 2026) ↓ 4 verdicts ↓
DermatologyGI/HepatologyWomen's Health Protein

Market cap $1.75B 171.6M shares (10-Q, Jul 31, 2026) × $10.17 close Nov 6, 2026

Most recent annual filing: 2026-03-24

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. ABS-201 AGA interim2H 2026ABS-201 AGA interim, 2H 2026, major
  2. ABS-201 Endometriosis Ph2 start4Q 2026ABS-201 Endometriosis Ph2 start, 4Q 2026, notable
  3. ABS-201 AGA toplineEarly 2027ABS-201 AGA topline, Early 2027, thesis-defining
  4. ABS-201 Ph2 topline2H 2027ABS-201 Ph2 topline, 2H 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (6 active programs)

Technology platforms

Integrated Drug Creation

AI-native antibody drug creation platform combining Origin-1 generative design model with lab-in-the-loop wet lab validation; supports de novo antibody design, multi-parametric lead optimization, and reverse immunology; applicable across oncology, immunology, inflammation, and other therapeutic areas with significant unmet medical need

Origin-1

De novo full-length monoclonal antibody design platform targeting zero-prior epitopes; generates epitope-specific, atomically accurate binders with functional potency; validated against four targets including COL6A3 and AZGP1 by cryo-EM; feeds into Integrated Drug Creation platform

Integrated Drug Creation · AMD

AI-native integrated drug creation platform combining Origin-1 generative design model with lab-in-the-loop rapid validation; supports de novo antibody design, multi-parametric lead optimization, and reverse immunology across oncology, immunology, and inflammation disease areas.

Origin

Generative AI platform for de novo antibody design; enables design of therapeutic candidates against challenging targets including prolactin receptor biology across multiple therapeutic areas

Targets: PRLR

ATLAS

Absci's drug discovery and design platform referenced in forward-looking statements alongside the company's generative AI approach

AbsciDesign

De novo AI antibody design platform using structure and sequence inputs to generate and experimentally validate therapeutic antibody candidates; focus areas include antibody-based therapeutics across immunology, inflammation, and metabolism

Capital (as filed)

Cash
$108M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$93.3M Jun 30, 2026
Operating cash flow
−$27.6M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$201M cash, runway 2H 2028 per the update of Aug 11, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Absci, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-05-04 Watch Absci Corp (ABSI) - Scientific Deep Dive for ABS-101, ABS-201, and Pipeline Products ABS-201 is a high-risk binary bet on a novel AI-designed antibody mechanism; wait on the sidelines until the Phase 1/2a safety/ADA readout removes existential biologic risk before entering.
  2. 2026-05-08 Speculative buy speculative UPDATE: Absci (ABSI) - The AI Didn't Hallucinate (Yet) SAD cohorts completed with clean tolerability and preliminary PK supporting the 2-3 dose/6-month dosing thesis, retiring the most catastrophic immunogenicity risk and warranting a starter/lottery-ticket position ahead of Q2 ADA confirmation.
  3. 2026-06-24 Buy core UPDATE: Absci (ABSI) - Lilly Shows Up, ADAs Don't The 65-day half-life landed in humans, ADAs showed no apparent PK impact, and Eli Lilly anchored a $100M raise at $7.41, retiring the bear case and validating the commercial dosing thesis and M&A optionality.
  4. 2026-08-12 Buy core UPDATE: Absci (ABSI) - The Genetics Slide Nobody Read New UK Biobank Mendelian randomization data causally implicates PRLR in pattern hair loss, cash runway extended to 2H 2028, and MAD Cohort 3 enrolling on schedule; the -12.5% down day is post-run-up digestion, not a fundamental repricing.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (23)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 20, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

4 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)